Clinical Trials Using Dasatinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dasatinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-22 of 22
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1193 locations

  • Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

    This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia cells produce a protein called BCR-ABL. The BCR-ABL protein helps chronic myeloid leukemia cells to grow and divide. Tyrosine kinase inhibitors, such as bosutinib, dasatinib, and nilotinib, stop the BCR-ABL protein from working, which helps to reduce the amount of chronic myeloid leukemia cells in the body. Ruxolitinib is a different type of drug that helps to stop the body from making substances called growth factors. Chronic myeloid leukemia cells need growth factors to grow and divide. The addition of ruxolitinib to the tyrosine kinase inhibitor may or may not help reduce the amount of chronic myeloid leukemia cells in the body.
    Location: 504 locations

  • Testing Pembrolizumab with Existing Cancer Therapy in Patients with Evidence of Residual Chronic Myelogenous Leukemia

    This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia compared to dasatinib, imatinib mesylate, or nilotinib alone.
    Location: 230 locations

  • Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia

    This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.
    Location: 135 locations

  • Risk Classification Schemes in Identifying Better Treatment Options for Children and Adolescents with Acute Lymphoblastic Leukemia

    This randomized phase III trial studies risk classification schemes in identifying better treatment options for children and adolescents with acute lymphoblastic leukemia. Risk factor classification may help identify how strong treatment should be for patients with acute lymphoblastic leukemia.
    Location: 7 locations

  • Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma

    This randomized phase II / III trial studies the side effects of combination chemotherapy and how well it works in treating patients with acute lymphoblastic leukemia or lymphoma. Drugs used in combination chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 5 locations

  • A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

    The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.
    Location: 5 locations

  • Ruxolitinib and Tyrosine Kinase Inhibitors for the Treatment of Recurrent Chronic Phase-Chronic Myeloid Leukemia

    This phase II trial studies how well ruxolitinib and tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib, nilotinib or bosutinib, work in treating patients who are attempting to stop TKI medications for a second time for chronic phase-chronic myeloid leukemia that has come back (recurrent). Ruxolitinib and imatinib, dasatinib, nilotinib or bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. The purpose of this trial is to see if adding ruxolitinib to imatinib, dasatinib, nilotinib or bosutinib works better in prolonging treatment-free remission in patients with chronic phase-chronic myeloid leukemia.
    Location: 3 locations

  • ABL001, Dasatinib, and Prednisone in Treating Patients with BCR-ABL Positive B-Cell Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia

    This phase I trial studies the side effects and best dose of ABL001 when given together with dasatinib and prednisone in treating patients with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia. ABL001 and dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Prednisone may help to lessen inflammation and lower the body's immune response. Giving ABL001, dasatinib, and prednisone may work better in treating patients with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia.
    Location: 3 locations

  • Dasatinib for the Treatment of Waldenstrom Macroglobulinemia in Patients Progressing on Ibrutinib

    This trial studies the side effects of dasatinib for the treatment of Waldenstrom macroglobulinemia that is progressing on ibrutinib. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is a targeted therapy intended to treat your cancer by binding to the target protein called BTK. BTK is believed to be an important target for treatment of patients with specific gene mutations. Some patients who have disease progression after taking ibrutinib have these gene mutations. This study may help doctors assess the feasibility of using dasatinib as a possible treatment for Waldenstrom macroglobulinemia that is progressing on ibrutinib.
    Location: 2 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
    Location: 3 locations

  • Palbociclib and Combination Chemotherapy in Treating Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

    This phase I trial studies how well palbociclib and combination chemotherapy work in treating pediatric patients with acute lymphoblastic leukemia that has come back or does not respond to treatment. Palbociclib, dasatinib, and ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, bortezomib, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib and combination chemotherapy may work better in treating pediatric patients with acute lymphoblastic leukemia.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Dasatinib and Everolimus in Treating Children with Newly Diagnosed, Recurrent, or Progressive High-Grade Glioma with PDGFR Alterations

    This phase II trial studies how well dasatinib and everolimus work in treating children with high-grade glioma with PDGFR alterations that is newly diagnosed, has come back, or is growing, spreading or getting worse. Dasatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Ganitumab and Dasatinib in Treating Patients with Relapsed or Refractory Embryonal or Alveolar Rhabdomyosarcoma

    This phase I / II trial studies the side effects and best dose of dasatinib when given together with ganitumab and to see how well they work in treating patients with embryonal and alveolar rhabdomyosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with ganitumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving dasatinib and ganitumab may work better in treating patients with embryonal and alveolar rhabdomyosarcoma compared to standard treatment, including surgery, radiation, and / or chemotherapy.
    Location: 2 locations

  • Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

    The primary objective of the Phase Ib study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 in combination with dasatinib in patients with with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) including chronic phase patients who have failed initial tyrosine kinase inhibitor (TKI) therapy, accelerated or blast phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS). The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and dasatinib in patients with Ph+ CML, Ph+AML, or high-risk Ph+ MDS.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Dasatinib and Venetoclax in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

    This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

    This phase II trial studies the side effects and best dose of ruxolitinib phosphate and how well it works compared to dasatinib when given with chemotherapy in treating patients with Philadelphia chromosome-like acute lymphoblastic leukemia that has come back or has not responded to treatment. Ruxolitinib phosphate and dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving ruxolitinib phosphate or dasatinib with chemotherapy works better in treating patients with previously treated acute lymphoblastic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients with Advanced, Recurrent, or Refractory Solid Tumors

    This phase I trial studies the side effects and best dose of dasatinib and temsirolimus when given together with cyclophosphamide in treating patients with solid tumors that have spread to other places in the body, have come back, or have not respond to previous treatment. Dasatinib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving dasatinib and temsirolimus together with cyclophosphamide may be a better treatment for advanced solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Intensive Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This partially randomized phase II trial studies how well intensive combination chemotherapy works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as daunorubicin hydrochloride, cyclophosphamide, vincristine sulfate, prednisone, leucovorin calcium, cytarabine, etoposide, and liposomal cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Biological therapies, such as mercaptopurine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Dietary supplements, such as levocarnitine, may reduce the incidence of liver damage. Pegaspargase, methotrexate, dasatinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with, rituximab, mercaptopurine, levocarnitine, pegaspargase, methotrexate, dasatinib and imatinib mesylate may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Location: 3 locations

  • Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage IV Colorectal Cancer Receiving FOLFOX Regimen and Bevacizumab

    This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with stage IV colorectal cancer who are receiving FOLFOX regimen and bevacizumab. Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin (FOLFOX regimen), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. However, the buildup of oxaliplatin in the cranial nerves can result in damage or the nerves. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Blocking these enzymes may reduce oxaliplatin-induced peripheral neuropathy.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Dasatinib in Treating Patients with nEGFR Positive Stage I-III Triple-Negative Breast Cancer

    This phase II trial studies how well dasatinib works in treating patients with nuclear (n)EGFR stage I-III triple-negative breast cancer. nEGFR promotes tumor growth. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin